Kexing Biopharm Enters Overseas Partnership with Daguang Pharmaceutical to Expand Global Eye Care Market

Article source：May 22,2026View： 379

Recently, Kexing Biopharm and Guangzhou Daguang Pharmaceutical officially signed an overseas market cooperation agreement for a portfolio of eye drop products. The two companies will jointly promote three high-quality ophthalmic products in the Middle East, Southeast Asia, and Hong Kong (China). This collaboration further enriches Kexing Biopharm’s overseas ophthalmology product pipeline.

Expanding Ophthalmic Therapeutic Coverage Across Global Markets

The global ophthalmic pharmaceutical market reached USD 45.6 billion in 2025, representing a year-on-year growth of 10%. According to the 2025–2030 China Ophthalmic Drug Industry Market Landscape Survey and Investment Value Assessment Report by the China Research Institute of Industrial Development, the market is expected to maintain steady growth in the coming years.

Daguang Pharmaceutical has accumulated deep expertise in ophthalmic formulation development and manufacturing, supported by a mature product portfolio. The three ophthalmic products included in this cooperation are all clinically established medications with clear mechanisms of action and broad therapeutic applications.

Pheniramine Maleate and Naphazoline Hydrochloride Eye Drops are a compound over-the-counter ophthalmic solution.

Moxifloxacin Hydrochloride Eye Drops provide broad-spectrum antibacterial activity.

Olopatadine Hydrochloride Eye Drops are commonly used for the treatment of allergic conjunctivitis. They feature a dual-action mechanism: rapidly blocking histamine receptors to relieve itching within minutes, and stabilizing mast cells to inhibit inflammatory mediator release, thereby controlling allergic reactions at the source.

According to the agreement, all three products will be jointly developed in overseas markets including Saudi Arabia, Thailand, and Malaysia. In addition, Moxifloxacin Hydrochloride Eye Drops will also be introduced to Kuwait and Hong Kong (China). Kexing Biopharm will leverage its overseas commercialization platform to accelerate product registration and market entry, enabling more patients to benefit from high-quality ophthalmic therapies.

Strengthening Ophthalmology Portfolio and Global Commercialization Capabilities

Kexing Biopharm has long been committed to innovative drug development and global commercialization. In the ophthalmology field, the company has built a diversified product pipeline.

Its independently developed innovative candidate GB10, a high-concentration anti-VEGF/Ang-2 bispecific antibody fusion protein drug, represents an important pipeline asset in the treatment of retinal diseases. It received approval for clinical trials from the National Medical Products Administration (NMPA) at the end of last year.

In addition, the company has also introduced an Aflibercept biosimilar, which, together with the newly partnered Daguang Pharmaceutical eye drop products, will provide patients with a broader range of treatment options in the future.

Looking ahead, Kexing Biopharm will continue to adhere to its “innovation + internationalization” strategy. On one hand, it will accelerate the R&D and clinical advancement of innovative products; on the other, it will fully leverage its overseas commercialization platform to bring more high-quality medicines to global markets, offering patients more diverse and accessible treatment options.